Press Releases - 2023-12-19 (5)

Date	Title	Company
19-Dec-2023	Evaxion Biotech Announces Private Placement Financing	Evaxion Biotech A/S
19-Dec-2023	Cytomos unveils patented AuraCyt™ brand and launches new website for its transformative cell analysis technology	Cytomos
19-Dec-2023	Almirall to participate in the 42nd Annual J.P. Morgan Healthcare Conference	Almirall S.A. (BME: ALM),
19-Dec-2023	Otsuka and Ionis enter into licensing agreement covering Europe for hereditary angioedema	Otsuka Pharmaceutical Europe Ltd
19-Dec-2023	Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals	Biosynth
19-Dec-2023	New hot-flush treatment VEOZA▼™ (fezolinetant): first-in-class non-hormonal medicine for moderate to severe vasomotor symptoms associated with menopause licensed in Great Britain	Astellas Pharma Inc
19-Dec-2023	Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	Achilles Therapeutics
19-Dec-2023	Shionogi announces agreement with SOBI on Fetcroja®▼ (cefiderocol) to expand access for patients with infections due to aerobic Gram-negative organisms in adults with limited treatment options.	Shionogi B.V.
19-Dec-2023	Santhera’s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	Santhera Pharmaceuticals
19-Dec-2023	Recipharm Harmonises its Global Quality Operations with Veeva Vault Quality	Veeva Systems
19-Dec-2023	HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration	HERVOLUTION Therapeutics
19-Dec-2023	Shorla Oncology & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO, the First and Only Oral Methotrexate Solution Approved in the U.S. for Adults	Shorla Oncology
19-Dec-2023	ZOLL Reports Email Phishing Attack	Businesswire